Life Sciences(en) Archives - Page 2 of 2 - Castrén & Snellman

Biovian – Manufacturing facility project

In a constantly changing and challenging environment, the first rate expertise and experience of our team will help propel your life science company to success.

We can provide your company with the specialist knowledge needed to find solutions to key life science industry issues. We are a partner you can rely on in assignments focusing on, for example:

Pharmaceuticals & Medical Devices
Healthcare
Food Law
Public Procurement
IP Disputes
Data protection & Privacy
Outside Legal Counsel

We have solid experience of handling assignments for Finnish and international pharmaceutical companies, health service providers as well as biotech and food industry companies. In international assignments we can provide you with in-depth insight into the Finnish legal environment and practical solutions for business needs.

Our excellence has been noted in ratings by Best Lawyers, Intellectual Asset Management (IAM), Chambers Global, Chambers Europe, Who’s Who Legal and PLC.

Latest references

Aurevia and Labquality – Strategic reorganisation

We advised Aurevia Oy, a portfolio company of French private equity sponsor Mérieux Equity Partners, in a strategic reorganisation that involved splitting Aurevia and its parent companies into two independent groups of companies and reorganisation of its existing debt-financing arrangements. Following the reorganisation, the newly formed Aurevia continues as a leading provider of Contract Research Organization (CRO) and Quality Assurance and Regulatory Affairs (QARA) services, while the newly formed Labquality focuses on delivering External Quality Assessment (EQA) services. Aurevia serves operators in the medical devices, in vitro diagnostics and pharmaceutical sectors. Labquality’s customers include clinical laboratories and social and healthcare organisations. The reorganisation positions Aurevia and Labquality to allocate investments more effectively, accelerate growth within their respective customer segments, and respond to evolving market and client needs. The transaction was implemented through multiple parallel demergers and required comprehensive legal and tax structuring across several jurisdictions. Our team supported Aurevia throughout the planning and implementation phases, covering corporate, tax, employment law, and regulatory matters, as well as the optimisation of each group’s financing structure.

Finnsusp – Sale of eyeglass lens business

We advised Oy Finnsusp Ab in the sale of its eyeglass lens business to IXI Optics Oy, subsidiary of a Finnish technology company IXI Eyewear. Finnsusp has been the only Finnish company manufacturing eyeglass lenses for over 35 years. Following the sale of its business, the company will focus on its international core business, specifically on the development and manufacturing of dry eye products and contact lens care solutions. Oy Finnsusp Ab (Piiloset) is a Finnish family-owned medical device manufacturer founded in 1978. In addition to Finland, the company’s products are sold in more than 35 countries in Europe, South and North America, the Middle East, and Africa. IXI Eyewear Oy is a Finnish technology startup that develops dynamic smart glasses based on liquid crystal technology.

KKR – Acquisition of Karo Healthcare

We acted as Finnish legal adviser to KKR in connection with its acquisition of the entire share capital of Karo Healthcare from EQT. The transaction follows Karo’s significant strategic transformation from a Nordic specialty pharma business into a leading pan-European consumer healthcare platform, with an attractive product portfolio spanning core categories such as Skin Health, Foot Health, and Intimate Health, as well as Digestive Health and Vitamins, Minerals & Supplements. KKR & Co. Inc. (NYSE: KKR), is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. Completion of the transaction is subject to customary conditions and regulatory approvals. The transaction is expected to close in the coming months.

Trety – Dispute and settlement negotiations concerning a development and production agreement

We successfully represented Trety AB in a dispute and settlement negotiations concerning an agreement for development and production of communication devices for the healthcare sector. Eventually, the parties reached an amicable settlement to the full satisfaction of our client and thus the parties avoided an extensive arbitral proceeding. Trety AB is a global company that provides its customers with solutions for development, industrialization and production of electronics. Trety AB has over 30 years’ experience from IT, electronics and telecommunication industries.

Latest insights

2.5.2024 – Private Equity Strong momentum in life sciences and health tech industry: Castrén & Snellman sees a significant uptick in deal-making

Karlo Siirala

Hanna Paloheimo

Sakari Lukinmaa

Tero Tuomisto

Antti Kaakkola

Karlo Siirala, Hanna Paloheimo, Sakari Lukinmaa, Tero Tuomisto & Antti Kaakkola

30.3.2026 – Competition & Procurement Finnish FDI screening under reform — Update following the stakeholder consultation

Kiti Karvinen

Johanna Kyllöinen

Joachim Wik

Kiti Karvinen, Johanna Kyllöinen & Joachim Wik

3.3.2026 – Employment The threshold for dismissal is lowered: what should be taken into account in practice?

Aleksandra Särkelä

Aleksandra Särkelä

2.3.2026 – Environment, Energy & Green Transition Energy security is a matter of investment and competitiveness

Samuli Tarkiainen

Marius af Schultén

Samuli Tarkiainen & Marius af Schultén

Search from the site.